Brief: Vivani Medical Provides Update On Clinical Development Plans For Npm-139 Semaglutide Implant For Chronic Weight Management
04/09/2025 16:27
Vivani Medical Inc VANI.O: VIVANI MEDICAL PROVIDES UPDATE ON CLINICAL DEVELOPMENT PLANS FOR NPM-139 SEMAGLUTIDE IMPLANT FOR CHRONIC WEIGHT MANAGEMENT VIVANI MEDICAL INC - TO INITIATE PHASE 1 STUDY FOR NPM-139 IN 2026 Source text: ID:nGNXbVZGZX Further company coverage: VANI.O
Recent news on Vivani Medical
See all newsVivani Medical Q2 net loss narrows as expenses fall
Vivani Medical Inc reports results for the quarter ended June 30 - Earnings Summary
Vivani Medical Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia